#oncology #IDEAYA Biosciences #Precision Medicine

IDEAYA Biosciences to Participate in February 2026 Investor Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a pioneer in precision medicine focusing on oncology, is gearing up to engage with investors through several significant events in February 2026, showcasing their commitment to advancing targeted therapeutics. The company specializes in creating innovative solutions for cancer therapy, and its upcoming presentations will delve into their latest discoveries and developments.

Upcoming Events

IDEAYA's involvement in investor relations will include notable events on February 18 and February 23, 2026. The first, the Citi's 2026 Virtual Oncology Leadership Summit on February 18, will feature a fireside chat with prominent figures from the company. Chief Medical Officer Darrin Beaupre, Chief Scientific Officer Michael White, and Chief Financial Officer Joshua Bleharski will discuss strategic insights, led by Ph.D. Director Yigal D. Nochomovitz, a seasoned analyst in the biotech space. This discussion will provide attendees with a comprehensive view of IDEAYA's operations, goals, and innovations in oncology.

Following that, IDEAYA will host a Virtual Fireside Chat on February 23 at 12 PM ET, facilitated by Umer Raffat, Senior Managing Director of Biotech and Pharma Equity Research at Evercore ISI. This session will include CEO Yujiro S. Hata, along with the same key leadership team members who participated in the first event. This chat promises to engage a broader audience, offering insights into IDEAYA's pipeline and research directions in the landscape of precision medicine.

Accessing the Events

For those interested in viewing these presentations, IDEAYA Biosciences will provide a live audio webcast during both events, available on their website under the